Document Detail

Limited treatment with beta-1,3/1,6-glucan improves production values of broiler chickens challenged with Escherichia coli.
MedLine Citation:
PMID:  16615344     Owner:  NLM     Status:  MEDLINE    
The development of antibiotic-resistant bacteria has led to a need for alternatives to antibiotics for growth promotion and disease prevention in poultry production. The helical polysaccharide beta-1,3/1,6-glucan is derived from the cell wall of Saccharomyces cervisiae and has immunomodulating activities. The objective of this study was to determine the ability of 2 supplementation programs with a commercial beta-1,3/1,6-glucan product to protect broiler chicks from experimental respiratory challenge with Escherichia coli. Chicks were housed in battery-brooders from 1 d of age and fed a standard starter diet or the same diet containing 20 g/ton (22 ppm) of purified beta-1,3/1,6-glucan either continuously (BG25d) or for only the first 7 d prior to challenge (BG7d). At d 7 one-half of the birds were inoculated in the thoracic air sac with 800 cfu of a serotype O2, nonmotile strain of E. coli. All surviving birds were necropsied at d 25. Body weight of survivors and feed conversion efficiency were protected from the adverse effects of E. coli challenge by BG7d but not by BG25d. Mortality was nominally decreased from 63% (control) to 53% in BG25d and 47% in BG7d, but these decreases were not significant. The relative weights of the liver and heart were increased, and the bursa of Fabricius relative weights were decreased by E. coli challenge, and these effects were modulated by beta-glucan treatment. Despite positive effects of BG7d in E. coli-challenged birds, the BW of nonchallenged birds was decreased by BG7d and BG25d. These results suggest that supplementation of broiler diets with beta-1,3/1,6-glucan may be valuable for decreasing production losses due to E. coli respiratory disease, but that the immune stimulation provided may also result in decreased production values under experimental battery conditions or for birds raised in an environment with minimal disease challenges.
G R Huff; W E Huff; N C Rath; G Tellez
Related Documents :
9789764 - The study of riboflavin requirement in broiler chickens.
17626804 - Performance of turkey poults fed different doses of aflatoxins in the diet.
7877934 - Growth, livability, and feed conversion of 1957 vs 1991 broilers when fed "typical" 195...
16050124 - Utilization of metabolizable energy by young broilers and birds of intermediate growth ...
3700584 - Plasma catecholamines, dietary carbohydrate, and glucose intolerance: a comparison betw...
20368524 - Apolipoprotein c-iii and the metabolic basis for hypertriglyceridemia and the dense low...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Poultry science     Volume:  85     ISSN:  0032-5791     ISO Abbreviation:  Poult. Sci.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-17     Completed Date:  2006-05-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401150     Medline TA:  Poult Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  613-8     Citation Subset:  IM    
USDA, Agricultural Research Service, Poultry Production and Product Safety Research, and Department of Poultry Science, University of Arkansas, Fayetteville 72701, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chickens / microbiology
Escherichia coli Infections / microbiology,  prevention & control,  veterinary*
Glucans / pharmacology*,  therapeutic use
Poultry Diseases / drug therapy,  microbiology,  prevention & control*
Reg. No./Substance:
0/Glucans; 0/epiglucan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Single nucleotide polymorphism discovery in the avian Tapasin gene.
Next Document:  Apparent attachment of Campylobacter and Salmonella to broiler breeder rooster spermatozoa.